{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:03Z","timestamp":1790957583731,"version":"4.1.0"},"reference-count":72,"publisher":"Portland Press Ltd.","issue":"9","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:p>Chronic RAS (renin\u2013angiotensin system) activation by both AngII (angiotensin II) and aldosterone leads to hypertension and perpetuates a cascade of pro-hypertrophic, pro-inflammatory, pro-thrombotic and atherogenic effects associated with cardiovascular damage. In 2000, a new pathway consisting of ACE2 (angiotensin-converting enzyme2), Ang-(1\u20139) [angiotensin-(1\u20139)], Ang-(1\u20137) [angiotensin-(1\u20137)] and the Mas receptor was discovered. Activation of this novel pathway stimulates vasodilation, anti-hypertrophy and anti-hyperplasia. For some time, studies have focused mainly on ACE2, Ang-(1\u20137) and the Mas receptor, and their biological properties that counterbalance the ACE\/AngII\/AT1R (angiotensin type\u00a01 receptor) axis. No previous information about Ang-(1\u20139) suggested that this peptide had biological properties. However, recent data suggest that Ang-(1\u20139) protects the heart and blood vessels (and possibly the kidney) from adverse cardiovascular remodelling in patients with hypertension and\/or heart failure. These beneficial effects are not modified by the Mas receptor antagonist A779 [an Ang-(1\u20137) receptor blocker], but they are abolished by the AT2R (angiotensin type\u00a02 receptor) antagonist PD123319. Current information suggests that the beneficial effects of Ang-(1\u20139) are mediated via the AT2R. In the present review, we summarize the biological effects of the novel vasoactive peptide Ang-(1\u20139), providing new evidence of its cardiovascular-protective activity. We also discuss the potential mechanism by which this peptide prevents and ameliorates the cardiovascular damage induced by RAS activation.<\/jats:p>","DOI":"10.1042\/cs20130449","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T09:17:49Z","timestamp":1404379069000},"page":"549-557","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Recent insights and therapeutic perspectives of angiotensin-(1\u20139) in the cardiovascular system"],"prefix":"10.1042","volume":"127","author":[{"given":"Maria\u00a0Paz","family":"Ocaranza","sequence":"first","affiliation":[{"name":"Divisi\u00f3n de Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Michea","sequence":"additional","affiliation":[{"name":"Millennium Institute of Immunology and Immunotherapy, Universidad de Chile, Santiago, Chile"},{"name":"Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile"},{"name":"Advanced Center for Chronic Diseases (ACCDiS), Centro Estudios Moleculares de la Celula (CMEC), Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Chiong","sequence":"additional","affiliation":[{"name":"Advanced Center for Chronic Diseases (ACCDiS), Centro Estudios Moleculares de la Celula (CMEC), Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos\u00a0F.","family":"Lagos","sequence":"additional","affiliation":[{"name":"Departamento de Endocrinolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lavandero","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile"},{"name":"Advanced Center for Chronic Diseases (ACCDiS), Centro Estudios Moleculares de la Celula (CMEC), Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile"},{"name":"Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge\u00a0E.","family":"Jalil","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"key":"2021113010332515200_B1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/01.HYP.0000193538.20705.23","article-title":"The prothrombotic paradox of hypertension: role of the renin\u2013angiotensin and kallikrein\u2013kinin systems","volume":"46","author":"Dielis","year":"2005","journal-title":"Hypertension"},{"key":"2021113010332515200_B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3317\/jraas.2006.003","article-title":"Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research","volume":"7","author":"Ferrario","year":"2006","journal-title":"J. Renin Angiotensin Aldosterone. Syst."},{"key":"2021113010332515200_B3","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"2021113010332515200_B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1043-2760(99)00205-2","article-title":"Signal transduction from the angiotensin II AT2 receptor","volume":"11","author":"Nouet","year":"2000","journal-title":"Trends Endocrinol. Metab."},{"key":"2021113010332515200_B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1590\/S0100-879X2005000400003","article-title":"Cardiovascular actions of angiotensin-(1\u20137)","volume":"38","author":"Ferreira","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2021113010332515200_B6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0196-9781(89)90133-2","article-title":"Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin","volume":"10","author":"Johnson","year":"1989","journal-title":"Peptides"},{"key":"2021113010332515200_B7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0006-2952(90)90058-S","article-title":"Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II","volume":"39","author":"Drummer","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"2021113010332515200_B8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2\u00a0in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"key":"2021113010332515200_B9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/HJH.0b013e328335d291","article-title":"Angiotensin-(1\u20139) regulates cardiac hypertrophy in\u00a0vivo and in\u00a0vitro","volume":"28","author":"Ocaranza","year":"2010","journal-title":"J. Hypertens."},{"key":"2021113010332515200_B10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","article-title":"Angiotensin-(1\u20139) reverses experimental hypertension and cardiovascular damage by inhibition of the ACE\/AngII Axis","volume":"32","author":"Ocaranza","year":"2014","journal-title":"J. Hypertens."},{"key":"2021113010332515200_B11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.HYP.22.4.513","article-title":"Nephrectomy, converting enzyme inhibition, and angiotensin peptides","volume":"22","author":"Campbell","year":"1993","journal-title":"Hypertension"},{"key":"2021113010332515200_B12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/01.HYP.18.6.763","article-title":"Differential regulation of angiotensin peptide levels in plasma and kidney of the rat","volume":"18","author":"Campbell","year":"1991","journal-title":"Hypertension"},{"key":"2021113010332515200_B13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/01.HYP.0000017283.67962.02","article-title":"Angiotensin 1\u20139 and 1\u20137 release in human heart: role of cathepsin A","volume":"39","author":"Jackman","year":"2002","journal-title":"Hypertension"},{"key":"2021113010332515200_B14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1161\/01.CIR.95.6.1455","article-title":"Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1\u20139) formed by heart carboxypeptidase A-like activity","volume":"95","author":"Kokkonen","year":"1997","journal-title":"Circulation"},{"key":"2021113010332515200_B15","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"2021113010332515200_B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysinin angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"2021113010332515200_B17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1113\/expphysiol.2007.040246","article-title":"Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart","volume":"93","author":"Garabelli","year":"2008","journal-title":"Exp. Physiol."},{"key":"2021113010332515200_B18","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1016\/S0021-9258(17)39531-5","article-title":"A human platelet angiotensin I-processing system. Identification of components and inhibition of angiotensin-converting enzyme by product","volume":"260","author":"Snyder","year":"1985","journal-title":"J. Biol. Chem."},{"key":"2021113010332515200_B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-4838(86)90125-1","article-title":"Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation","volume":"871","author":"Snyder","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010332515200_B20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/01.HYP.0000188905.20884.63","article-title":"Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors","volume":"46","author":"Chen","year":"2005","journal-title":"Hypertension"},{"key":"2021113010332515200_B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cardiores.2006.09.006","article-title":"ACE2 of the heart: From angiotensin I to angiotensin (1\u20137)","volume":"73","author":"Keidar","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"2021113010332515200_B22","doi-asserted-by":"publisher","first-page":"H3019","DOI":"10.1152\/ajpheart.01198.2006","article-title":"Primary role of angiotensin-converting enzyme-2\u00a0in cardiac production of angiotensin-(1\u20137) in transgenic Ren-2 hypertensive rats","volume":"292","author":"Trask","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113010332515200_B23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/HYPERTENSIONAHA.111.00318","article-title":"Network modeling reveals steps in angiotensin peptide processing","volume":"61","author":"Schwacke","year":"2013","journal-title":"Hypertension"},{"key":"2021113010332515200_B24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1113\/jphysiol.2010.203075","article-title":"Angiotensin 1\u20139 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type\u00a02 receptor","volume":"589","author":"Flores-Mu\u00f1oz","year":"2011","journal-title":"J. Physiol."},{"key":"2021113010332515200_B25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/HYPERTENSIONAHA.111.177485","article-title":"Angiotensin-(1\u20139) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type\u00a02 receptor","volume":"59","author":"Flores-Mu\u00f1oz","year":"2012","journal-title":"Hypertension"},{"key":"2021113010332515200_B26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.HYP.33.2.613","article-title":"Recent progress in angiotensin II type\u00a02 receptor research in the cardiovascular system","volume":"33","author":"Horiuchi","year":"1999","journal-title":"Hypertension"},{"key":"2021113010332515200_B27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/01.hjh.0000166845.49850.39","article-title":"Negative regulation of Rho\/Rho kinase by angiotensin II type\u00a02 receptor in vascular smooth muscle cells: role in angiotensin II- induced vasodilation in stroke-prone spontaneously hypertensive rats","volume":"23","author":"Savoia","year":"2005","journal-title":"J. Hypertens."},{"key":"2021113010332515200_B28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2007.11.006","article-title":"Over-expression of angiotensin II type\u00a02 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression","volume":"199","author":"Hu","year":"2008","journal-title":"Atherosclerosis"},{"key":"2021113010332515200_B29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1586\/14779072.5.3.531","article-title":"Vasoactive peptides in cardiovascular (patho) physiology","volume":"5","author":"Callera","year":"2007","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2021113010332515200_B30","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1161\/hy1101.096109","article-title":"Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II-from large arteries to the microcirculation","volume":"38","author":"Henrion","year":"2001","journal-title":"Hypertension"},{"key":"2021113010332515200_B31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1161\/01.HYP.0000090323.58122.5C","article-title":"Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice","volume":"42","author":"Abadir","year":"2003","journal-title":"Hypertension"},{"key":"2021113010332515200_B32","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"12","author":"Lautner","year":"2013","journal-title":"Circ Res."},{"key":"2021113010332515200_B33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1006\/dbio.1997.8764","article-title":"The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns","volume":"192","author":"Price","year":"1997","journal-title":"Dev. Biol."},{"key":"2021113010332515200_B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/10641950601147937","article-title":"Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature","volume":"26","author":"Velazquez-Armenta","year":"2007","journal-title":"Hypertens. Pregnancy"},{"key":"2021113010332515200_B35","doi-asserted-by":"publisher","first-page":"e47916","DOI":"10.1371\/journal.pone.0047916","article-title":"Impact of AT2 receptor deficiency on postnatal cardiovascular development","volume":"7","author":"Biermann","year":"2012","journal-title":"PLoS ONE"},{"key":"2021113010332515200_B36","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1006\/jmcc.2002.2080","article-title":"Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin","volume":"34","author":"Erd\u00f6s","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2021113010332515200_B37","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type\u00a01 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type\u00a02 receptors","volume":"99","author":"Liu","year":"1997","journal-title":"J. Clin. Invest."},{"key":"2021113010332515200_B38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1074\/jbc.M111.273052","article-title":"Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type\u00a01 (non-AT1), non-AT2 angiotensin binding site","volume":"287","author":"Wangler","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021113010332515200_B39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0076-6879(95)48034-X","article-title":"Thimet oligopeptidase and oligopeptidase M or neurolysin","volume":"248","author":"Serizawa","year":"1995","journal-title":"Methods Enzymol."},{"key":"2021113010332515200_B40","doi-asserted-by":"publisher","first-page":"27266","DOI":"10.1074\/jbc.270.45.27266","article-title":"Molecular cloning and expression of rat brain endopeptidase 3.4.24.16","volume":"270","author":"Dauch","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2021113010332515200_B41","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1523\/JNEUROSCI.16-16-05049.1996","article-title":"Distinct properties of neuronal and astrocytic endopeptidase 3.4.24.16: a study on differentiation, subcellular distribution, and secretion processes","volume":"16","author":"Vincent","year":"1996","journal-title":"J. Neurosci."},{"key":"2021113010332515200_B42","doi-asserted-by":"publisher","first-page":"15313","DOI":"10.1074\/jbc.272.24.15313","article-title":"Targeting of endopeptidase 24.16 to different subcellular compartments by alternative promoter usage","volume":"272","author":"Kato","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2021113010332515200_B43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12020-013-9898-x","article-title":"Pharmacological characterization of a novel non-AT1, non-AT2 angiotensin binding site identified as neurolysin","volume":"44","author":"Swindle","year":"2013","journal-title":"Endocrine"},{"key":"2021113010332515200_B44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0197-0186(88)90174-X","article-title":"Further characterization of a neurotensin-degrading neutral metalloendopeptidase from rat brain","volume":"12","author":"Barelli","year":"1988","journal-title":"Neurochem. Int."},{"key":"2021113010332515200_B45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1432-1033.1992.tb17168.x","article-title":"Purification of the main somatostatin degrading proteases from rat and pig brains, their action on other neuropeptides, and their identification as endopeptidases 24.15 and 24.16","volume":"208","author":"Dahms","year":"1992","journal-title":"Eur. J. Biochem."},{"key":"2021113010332515200_B46","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1073\/pnas.051633198","article-title":"Structure of neurolysin reveals a deep channel that limits substrate access","volume":"98","author":"Brown","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010332515200_B47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0006-8993(95)01260-5","article-title":"Purification and characterization of human endopeptidase 3.4.24.16. Comparison with the porcine counterpart indicates a unique cleavage site on neurotensin","volume":"709","author":"Vincent","year":"1996","journal-title":"Brain Res."},{"key":"2021113010332515200_B48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1006\/bbrc.1998.8941","article-title":"Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant endopeptidase 3.4.24.15","volume":"250","author":"Rioli","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113010332515200_B49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/MNH.0b013e3283414d40","article-title":"New insights into angiotensin receptor actions: from blood pressure to aging","volume":"20","author":"Stegbauer","year":"2011","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"2021113010332515200_B50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2010.08.081","article-title":"AT1 angiotensin II receptor and novel non-AT1, non-AT2 angiotensin II\/III binding site in brainstem cardiovascular regulatory centers of the spontaneously hypertensive rat","volume":"1359","author":"Bourassa","year":"2010","journal-title":"Brain Res."},{"key":"2021113010332515200_B51","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1074\/jbc.M109.074740","article-title":"Cell signaling, internalization, and nuclear localization of the angiotensin converting enzyme in smooth muscle and endothelial cells","volume":"285","author":"Lucero","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021113010332515200_B52","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.lfs.2013.10.020","article-title":"Stimulation of ANP by angiotensin-(1\u20139) via the angiotensin type\u00a02 receptor","volume":"93","author":"Cha","year":"2013","journal-title":"Life. Sci."},{"key":"2021113010332515200_B53","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/ATVBAHA.110.204453","article-title":"Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice","volume":"30","author":"Tesanovic","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010332515200_B54","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/01.HYP.0000215289.51180.5c","article-title":"Impairment of in\u00a0vitro and in\u00a0vivo heart function in angiotensin-(1\u20137) receptor MAS knockout mice","volume":"47","author":"Santos","year":"2006","journal-title":"Hypertension"},{"key":"2021113010332515200_B55","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1161\/01.HYP.0000127563.14064.fd","article-title":"Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer","volume":"43","author":"Metcalfe","year":"2004","journal-title":"Hypertension"},{"key":"2021113010332515200_B56","first-page":"317","article-title":"Angiotensin-(1\u20139), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats","volume":"61","author":"Kramkowski","year":"2010","journal-title":"J. Physiol. Pharmacol."},{"key":"2021113010332515200_B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1470320313498631","article-title":"Angiotensin-(1\u20139) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis","volume":"15","author":"Mogielnicki","year":"2014","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"2021113010332515200_B58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1160\/TH04-10-0701","article-title":"Angiotensin II enhances thrombosis development in renovascular hypertensive rats","volume":"93","author":"Mogielnicki","year":"2005","journal-title":"Thromb. Haemost."},{"key":"2021113010332515200_B59","first-page":"571","article-title":"Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats","volume":"56","author":"Kaminska","year":"2005","journal-title":"J. Physiol. Pharmacol."},{"key":"2021113010332515200_B60","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/HJH.0b013e3283440665","article-title":"Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1\u20139) axis in experimental hypertension","volume":"29","author":"Ocaranza","year":"2011","journal-title":"J. Hypertens."},{"key":"2021113010332515200_B61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/01.HYP.0000033224.99806.8A","article-title":"AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade","volume":"40","author":"Widdop","year":"2002","journal-title":"Hypertension"},{"key":"2021113010332515200_B62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/01.HYP.0000228997.88162.a8","article-title":"Angiotensin II type\u00a02 receptor-bradykinin B2 receptor functional heterodimerization","volume":"48","author":"Abadir","year":"2006","journal-title":"Hypertension"},{"key":"2021113010332515200_B63","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/377748a0","article-title":"Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor","volume":"377","author":"Ichiki","year":"1995","journal-title":"Nature"},{"key":"2021113010332515200_B64","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1172\/JCI7886","article-title":"Angiotensin II type\u00a02 receptor overexpression activates the vascular kinin system and causes vasodilation","volume":"104","author":"Tsutsumi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2021113010332515200_B65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1161\/HYPERTENSIONAHA.107.101717","article-title":"Effects of angiotensin type\u00a02 receptor overexpression in the rostral ventrolateral medulla on blood pressure","volume":"51","author":"Gao","year":"2008","journal-title":"Hypertension"},{"key":"2021113010332515200_B66","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/hy1201.096576","article-title":"Angiotensin type\u00a02 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats","volume":"38","author":"Carey","year":"2001","journal-title":"Hypertension"},{"key":"2021113010332515200_B67","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1476-5381.2009.00575.x","article-title":"Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats","volume":"159","author":"Bosnyak","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"2021113010332515200_B68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1470320309347786","article-title":"The angiotensin II type\u00a02 receptor and the kidney","volume":"11","author":"Siragy","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"2021113010332515200_B69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.ASN.0000043904.26730.11","article-title":"Pressure natriuresis in AT2 receptor-deficient mice with L-NAME hypertension","volume":"14","author":"Obst","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010332515200_B70","doi-asserted-by":"publisher","first-page":"F1430","DOI":"10.1152\/ajprenal.00218.2005","article-title":"Angiotensin II AT2 receptors inhibit proximal tubular Na+-K+-ATPase activity via a NO\/cGMP-dependent pathway","volume":"290","author":"Hakam","year":"2006","journal-title":"Am. J. Physiol. Reanl Physiol."},{"key":"2021113010332515200_B71","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1046\/j.1432-1033.2003.03573.x","article-title":"Comparison of the solution structures of angiotensin I and II. Implication for structure\u2013function relationship","volume":"270","author":"Spyroulias","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"2021113010332515200_B72","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.peptides.2007.08.011","article-title":"Study of angiotensin-(1\u20137) vasoactive peptide and its \u03b2-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies","volume":"28","author":"Lula","year":"2007","journal-title":"Peptides"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/127\/9\/549\/445851\/cs1270549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/127\/9\/549\/445851\/cs1270549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:25:56Z","timestamp":1638271556000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/127\/9\/549\/70762\/Recent-insights-and-therapeutic-perspectives-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,3]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20130449","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,3]]}}}